Skip to content

Bicarbonate v Saline to Prevent Contrast Nephropathy

Phase 4 Study of Bicarbonate Versus Saline Infusion Therapy to Prevent Contrast Induced Nephropathy (CAN-IT PREVENT Protocol)

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00384995
Enrollment
61
Registered
2006-10-06
Start date
2006-12-31
Completion date
2009-07-31
Last updated
2010-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast Media, Kidney Failure, Acute

Keywords

Contrast Induced Nephropathy, Chronic Kidney Disease, Acute Renal Failure, End-stage Renal Disease, Cardiovascular diseases, Coronary catheterization, Percutaneous coronary intervention, Intra-arterial angiography, Bicarbonate, Saline

Brief summary

Slowing of kidney function occurs in a minority of people given dye during angiography. The purpose of this study is to compare two different types of fluid given into a vein to reduce the risk of kidney injury: salt in water or baking soda in water.

Detailed description

A decline in kidney function after contrast is associated with prolonged hospital stay, adverse cardiac events, and higher mortality both in hospital and in the long term. Deliberate administration of fluids is recommended to reduce the risk of contrast nephropathy. However, data to support specific recommendations are lacking and the optimal fluid regimen remains unclear. It has been hypothesized that alkalinization of tubular fluid might be beneficial by reducing pH dependent free radical levels. A recent trial found a lower frequency of creatinine rise \> 25% within two days of contrast with a 7 hour infusion of isotonic sodium bicarbonate than with saline infusion (Merten GJ, JAMA 2004). However, it remains to be proven that bicarbonate is superior as this trial has a number of methodological flaws. Comparison: IV 1/6 M sodium bicarbonate OR IV 0.9% saline, each isotonic fluid given at the same rate of sodium administration (3.25 ml/Kg over 1 hour pre-contrast, followed by 1.1 ml/Kg/hr for 6 hours for bicarbonate; 3.5 ml/Kg over 1 hour pre-contrast, followed by 1.2 ml/Kg/hr for 6 hours for saline). Total infusion time 7 hours (for both). Maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular iso- or low-osmolality contrast in the minimal dose needed to complete the required imaging.

Interventions

DRUG0.9% (154 mEq/L) IV Sodium Chloride

Saline solution

DRUG1/6 M (166 mEq/L) IV Sodium Bicarbonate

Bicarbonate solution

Sponsors

European Commission
CollaboratorOTHER
Memorial University of Newfoundland
CollaboratorOTHER
Italian Society of Nephrology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Booked for cardiac or other non-renal arteriography * Pre-existing reduced kidney function: Serum Creatinine \>= 1.3 & \<= 4 mg/dl (female gender) or \>= 1.5 & \<= 5 mg/dl (male gender) * Age \> 18 years

Exclusion criteria

* GFR MDRD estimate \< 15 ml/min/m2 * End-stage renal disease already on dialysis * Known current Acute Kidney Failure with serum creatinine rise of \> 0.5 mg/dl within 24 hours * Pulmonary edema - current or within 48 hours * Clinically relevant ascites, edema or other fluid overload * Uncontrolled hypertension (\> 165 mmHg systolic, or \> 105 mmHg diastolic) * Hemodynamically unstable patient requiring IV nitroglycerine, or IV fluid or inotropes for blood pressure support * Emergency (unplanned) angiography * IV contrast procedure * Exposure to iodinated radiocontrast within 3 days prior to study * Prior anaphylactoid reaction to contrast * Planned administration of N-acetylcysteine * Planned administration of dopamine, fenoldopam or mannitol * Current pregnancy

Design outcomes

Primary

MeasureTime frame
Development of contrast-induced nephropathy, CIN, defined as an increase in serum creatinine of 25% or more from pre-intervention baseline to within 48-72 hours after administration of the radiographic contrast.48-72 hours

Secondary

MeasureTime frame
Days in hospital within the week post contrastOne week
Requirement for dialysisTwo months
Group mean change in serum creatinine48-72 hours
Major adverse cardiovascular eventsTwo months
DeathTwo months
Atheroembolic eventsTwo months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026